GFGorka Fernández-Eulate

Gorka Fernández-Eulate

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gorka Fernández-Eulate has a total of 270 co-authors. Here are the top co-authors by number of shared publications:

  • Anthony Behin

    Centre de Référence des maladies Neuromusculaires Nord/Est/Ile-de-France, Institut de Myologie, Hôpital Pitié-Salpêtrière, APHP, 47-83 bd de l'Hôpital, Paris 75013, France

    5 shared publications
  • Tanya Stojkovic

    Nord/Est/Ile-de-France Neuromuscular Diseases Reference Centre, Department of Neuro-Myology, Myology Institute, Pitié-Salpêtrière Hospital, Sorbonne Université, APHP , Paris 75013

    5 shared publications
  • Tanya Stojkovic

    Sorbonne Université, Service de Neuromyologie, Centre de référence Nord-Est-Ile-de-France, Institut de Myologie, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l’Hôpital 75651 Paris Cedex 13, Paris, France

    5 shared publications
  • Roberto Fernández-Torrón

    Neuromuscular Diseases Group, Neurosciences Area, Biogipuzkoa Health Research Institute, 20014 San Sebastian, Spain

    4 shared publications
  • Teresinha Evangelista

    Nord/Est/Ile-de-France Neuromuscular Diseases Reference Centre, Department of Neuro-Myology, Myology Institute, Pitié-Salpêtrière Hospital, Sorbonne Université, APHP , Paris 75013

    4 shared publications
  • Adolfo López de Munain

    CIBERNED, ISCIII (CIBER, Carlos III Institute, Spanish Ministry of Sciences and Innovation), Madrid, Spain

    3 shared publications

Latest Publications

  • Open Access

    Whole-Body Muscle MRI in Non-5q Spinal Muscular Atrophy

    by Edouard Berling, Harmen Reyngoudt, Adrien Le Guillou, Jean-Baptiste Noury, Pascal Cintas, Bruno Cadot, Isabelle Ackermann-Bonan, Benjamin Marty, Yves Fromes, Gorka Fernandez-Eulate, et al.

    Background and ObjectivesSpinal muscular atrophy (SMA) is a group of genetically heterogeneous motor neuron disorders characterized by progressive, predominantly proximal weakness. Non-5q SMA refer...


  • Open Access

    Systemic ELOVL6 activity predicts survival and represents a modifiable target of ALS

    by Andrés Jiménez-Zúñiga, Gorka Fernández-Eulate, José I. Ruíz-Sanz, Jose Luis Zúñiga-Elizari, Maddi Garciandia, Javier Riancho, Raul Domínguez, Ahmad Al Khleifat, Monica Zufiría, Sonia Alonso-Martin, et al.

    Background: Amyotrophic lateral sclerosis (ALS) is characterized by profound metabolic reprogramming, yet the lack of biomarkers for specific druggable targets remains a major hurdle for precision medicine. We hypothesized that peripheral lipid biosynthetic signatures could serve as both prognostic indicators and a roadmap for identifying novel disease-modifying targets. Methods: We assessed serum fatty acid (FA) metabolic pathways in two independent longitudinal cohorts (n = 37 and n = 38) using high-dimensional CoxBoost modeling. Primary outcomes were survival and functional staging milestones, including non-invasive ventilation and gastrostomy. The biological relevance of the identified candidate was further assessed through correlation with plasma neurofilament light-chain (NfL) levels. Causality and therapeutic potential were validated in Drosophila melanogaster models of TDP-43 proteinopathy via genetic ablation and pharmacological inhibition. Results: Our multi-parametric model, comprising two clinical variables and the estimated ELOVL6 (elongation of very long-chain fatty acids protein 6) activity, demonstrated robust prognostic accuracy (Uno’s C 0.69) across both cohorts; ELOVL6 activity served as a strong independent predictor of mortality and functional decline. Notably, high ELOVL6 activity significantly correlated with elevated plasma NfL levels (p < 0.01), linking peripheral elongation imbalances to central axonal damage. In Drosophila, ELOVL6 overactivation was identified as a conserved pathological consequence of TDP-43 dysfunction, characterized by an increased C18:0/C16:0 ratio in both loss-of-function and gain-of-function models. Inhibition of ELOVL6, either genetically or pharmacologically, rescued neuromuscular junction integrity, prolonged survival, and significantly reduced pathological TDP-43 phosphorylation in glial models. Conclusion: These findings position ELOVL6 as a promising modifiable metabolic node with potential for disease-modifying intervention in ALS. Beyond its potential utility for identifying high-risk metabolic profiles and assisting in prognostic counseling, ELOVL6 bridges systemic lipid dysregulation with TDP-43 proteinopathy. Targeting this pathway offers a dual opportunity: as a biological marker to supplement clinical staging and as a druggable enzymatic target to ameliorate motor neuron degeneration. HIGHLIGHTS: Systemic ELOVL6 activity is a robust independent predictor of ALS survival. High ELOVL6 levels correlate with plasma NfL and functional decline. Inhibition of ELOVL6 rescues NMJ integrity and survival in Drosophila models. Pharmacological targeting of ELOVL6 reduces glial TDP-43 phosphorylation. ELOVL6 represents a druggable metabolic node linking lipids to proteinopathy.


  • Pathophysiology of spinal motor neuron degeneration in latet-onset GM2 Gangliosidosis

    by Gorka Fernández García de Eulate

    Physiopathologie de la dégénérescence des motoneurones spinaux dans la forme adulte de la gangliosidose à GM2 à début tardif: La gangliosidose à GM2 est une maladie de surcharge lysosomale due à des mutations dans les gènes HEXA et HEXB, entrainant un déficit de la β-hexosaminidase A (HexA) et une accumulation de ganglioside GM2. Les manifestations neurologiques sont hétérogènes et peuvent débuter à tout âge selon le degré de déficit enzymatique. Dans la forme de l'adulte, l'atteinte motrice liée à la dégénérescence du motoneurone spinal (SMN) est la plus précoce, fréquente et invalidante de toutes les manifestations cliniques, non observée chez l'enfant. Les mécanismes de cette dégénérescence restent inconnus, en l'absence de modèle animal pertinent. J'ai établi un nouveau modèle cellulaire de la forme tardive de gangliosidose à GM2, en utilisant des SMN dérivés de cellules souches pluripotentes induites de trois patientes adultes. J'ai confirmé une réduction de la sous-unité α de l'HexA ainsi qu'une diminution de l'activité enzymatique de l'HexA. Les SMNs des patients montrent une accumulation précoce de GM2 ainsi que des modifications d'autres espèces de gangliosides GM1 et GM3 en chromatographie liquide couplée à la spectrométrie de masse. Cette accumulation est suivie par la formation d'amas de GM2 détectés par immunomarquage, partiellement colocalisés avec les marqueurs du lysosome (LAMP1) et de l'endosome tardif (RAB7). A des stades plus avancés de maturation, j'ai observé des anomalies morphologiques lysosomales, incluant une intensité globale augmenté de LAMP1 et des lysosomes élargis, en immunomarquage et microscopie électronique. Ces lysosomes élargis contenaient du matériel membranaire organisé en couches parallèles, rappelant les corps cytoplasmiques membraneux observés dans le tissu cérébral de patients. Un traitement avec Venglustat, un inhibiteur de la glucosylcéramide synthase, à des concentrations de 1-3 μM, a efficacement réduit les amas de GM2 lorsqu'il était appliqué très précocement, avec un effet beaucoup plus partiel lorsque le traitement était administré à un stade plus tardif. Des concentrations plus élevées (> 4 μM) induisaient une neurodégénérescence. Malgré une accumulation de GM2 et des anomalies lysosomales, les SMN issus de patientes ne présentaient pas d'anomalie de la neuritogenèse ni une dégénérescence précoce. En revanche, leur activité neuronale était altérée dans les enregistrements sur microélectrodes. L'analyse transcriptomique à deux stades du développement, stade de SMN jeune (jour 14) et stade de SMN mature (jour 28), a confirmé la différenciation et la maturation réussies des SMN, ainsi qu'une expression similaire des marqueurs d'identité des motoneurones entre patientes et témoins, suggérant une trajectoire neurodéveloppementale comparable. L'analyse d'enrichissement a révélé une dérégulation des gènes codant pour la synapse au jour 28. L'analyse des gènes différentiellement exprimés a montré que ceux codant pour des canaux ioniques ou des protéines régulatrices (DPP6, KCNV1, RGS8), la synapse glutamatergique (GLRA1 et GRIP2) et le système endolysosomal (CTSF, PLIN3 et ARHGAP26) figuraient parmi les plus altérés. De plus, la réduction du ganglioside GM2 par le Venglustat a diminué la surexpression de RGS8 et CTSF, avec une diminution non significative de la surexpression de KCNV1 et PLIN3, et une augmentation de la sous-expression d'ARHGAP26. En conclusion, j'ai généré et caractérisé un modèle cellulaire pertinent pour l'étude de la dégénérescence des SMN dans la gangliosidose à GM2 à début tardif. Ce modèle reproduit les principales caractéristiques pathologiques de la maladie et développe d'importantes altérations lysosomales. De plus, les SMN dérivés de patientes présentent une activité neuronale altérée ainsi qu'une dérégulation précoce des gènes synaptiques. Ce modèle in vitro peut servir de plateforme pour tester des thérapies émergentes, et les stratégies visant à corriger les anomalies de la membrane synaptique pourraient représenter une nouvelle voie thérapeutique.

  • Open Access

    DAB2 in LGMD R2: a molecular link between disease progression and lipid dysregulation

    by Celine Bruge, Nathalie Bourg, Emilie Pellier, Quentin Miagoux, Manon Benabides, Noella Grossi, Hassan Hayat, Margot Jarrige, Helene Polveche, Valeria Agostini, et al.

    Limb-girdle muscular dystrophy R2 (LGMD R2) is an autosomal recessive disorder caused by dysferlin deficiency, leading to progressive muscle weakness and wasting. The lack of reliable clinical biomarkers has limited disease monitoring and therapeutic evaluation. Here, we identified Disabled-2 (DAB2) as a molecular and clinical indicator of disease state in LGMD R2. Transcriptomic profiling revealed a significant upregulation of DAB2 in induced pluripotent stem cell–derived (iPSC-derived) myotubes from patients, a finding validated in muscle biopsies from 14 dysferlin-deficient individuals and in dysferlin-deficient Bla/J mice, where DAB2 levels increased with disease progression. Importantly, AAV-mediated expression of full-length dysferlin restored DAB2 levels, supporting its value as a dynamic readout of disease activity for both disease monitoring and therapeutic response. Given the established role of DAB2 in clathrin-mediated endocytosis, particularly in LDL receptor internalization and cholesterol homeostasis, and the pathological lipid accumulation reported in LGMD R2, we investigated its contribution to lipid dysregulation. High DAB2 expression paralleled lipid deposition in patient muscles, iPSC-derived myotubes, and mouse tissue, whereas siRNA-mediated DAB2 knockdown reduced lipid accumulation in LGMD R2 myotubes. Collectively, these findings suggest that DAB2 functions as a mechanistic link between dysferlin deficiency, altered lipid handling, and disease severity, and they highlight its potential as a prognostic marker and therapeutic response measure for LGMD R2.


  • Open Access

    Disease spectrum and long-term prognosis of patients with BAG3 -associated neuromuscular diseases in Europe

    by Gorka Fernández-Eulate, Cyril Gitiaux, Simone Thiele, Heinz Jungbluth, Anna Potulska-Chromik, Chiara Marini-Bettolo, Jean Baptiste Davion, Germán Morís, Eduard Gallardo, Montse Olivé, et al.

    De novo or autosomal dominant BAG3 gene variants cause a wide range of skeletal and cardiac muscle diseases encompassing Charcot–Marie–Tooth disease, myofibrillar myopathy, cardiomyopathy or a combination of them. Given the severity and rarity of BAG3-neuromuscular diseases (NMDs), series of patients are lacking. Our aim was to characterize the clinical and genetic spectrum, in addition to the natural history of BAG3-NMDs in Europe. In this multicentre retrospective study, we collected clinical, ancillary and genetic data of patients with NMD and BAG3 variants, identified from European paediatric and adult neuromuscular reference centres from May to December 2023 following a call circulated through the European Reference Network EURO-NMD and other partners. Responses were received from 35 centres in 17 countries. Twenty-six patients (65.4% males, 34.6% females) with BAG3-NMD from 18 different families were included in the study. The c.626C>T p.(Pro209Leu) variant, carried by 16 patients, was the only recurrent variant and was associated with a homogeneous and severe phenotype, with predominantly lower limb motor weakness (n = 13, 81.25%) or heart failure (n = 3, 18.75%) as the presenting feature and with a mean age at symptom onset of 7.8 ± 3.4 years. Where available (n = 13), electroneuromyography showed a polyneuropathy with demyelinating features and a frequently associated myopathy. Eleven (68.8%) patients had restrictive cardiomyopathy on initial assessment. Orthopaedic manifestations were common, with contractures (n = 15, 93.8%), foot deformities (n = 11, 84.6%) and scoliosis and/or rigid spine (n = 12, 80%). At last follow-up (age 21.5 ± 8.6 years) of the patients carrying the p.(Pro209Leu) variant, 10 (62.5%) had lost ambulation, 14 (93.3%) had respiratory insufficiency (11 requiring ventilation) and 12 (75%) had a restrictive cardiomyopathy, leading to heart failure and heart transplantation in five and four patients, respectively. Eight (50%) patients died prematurely at a mean age of 22.5 ± 9.6 years, most frequently from sudden death (n = 5). The other 10 patients carried three other BAG3 variants and showed a milder disease course, with all patients remaining ambulatory, without cardiorespiratory manifestations at last follow-up. The p.(Arg309*) nonsense variant, known to cause isolated dilated cardiomyopathy, and the p.(Val505Glyfs*6) frameshift variant, resulting in a premature stop codon, caused distal hereditary motor neuropathy. This is the largest study of patients with BAG3-NMD, delineating the frequency, specific presentation and natural history in patients with the recurrent BAG3 p.(Pro209Leu) missense variant, crucial for informing patient management in the context of a rapidly progressive disease. All other BAG3 variants were rare and caused milder clinical presentations.


  • Open Access

    Dysregulated FOXO1 activity drives skeletal muscle intrinsic dysfunction in amyotrophic lateral sclerosis

    by Mónica Zufiría, Oihane Pikatza-Menoio, Maddi Garciandia-Arcelus, Xabier Bengoetxea, Andrés Jiménez, Amaia Elicegui, María Levchuk, Olatz Arnold-García, Jon Ondaro, Pablo Iruzubieta, et al.

    Amyotrophic Lateral Sclerosis (ALS) is a multisystemic neurodegenerative disorder, with accumulating evidence indicating metabolic disruptions in the skeletal muscle preceding disease symptoms, rather than them manifesting as a secondary consequence of motor neuron (MN) degeneration. Hence, energy homeostasis is deeply implicated in the complex physiopathology of ALS and skeletal muscle has emerged as a key therapeutic target. Here, we describe intrinsic abnormalities in ALS skeletal muscle, both in patient-derived muscle cells and in muscle cell lines with genetic knockdown of genes related to familial ALS, such as TARDBP (TDP-43) and FUS. We found a functional impairment of myogenesis that parallels defects of glucose oxidation in ALS muscle cells. We identified FOXO1 transcription factor as a key mediator of these metabolic and functional features in ALS muscle, via gene expression profiling and biochemical surveys in TDP-43 and FUS-silenced muscle progenitors. Strikingly, inhibition of FOXO1 mitigated the impaired myogenesis in both the genetically modified and the primary ALS myoblasts. In addition, specific in vivo conditional knockdown of TDP-43 or FUS orthologs (TBPH or caz) in Drosophila muscle precursor cells resulted in decreased innervation and profound dysfunction of motor nerve terminals and neuromuscular synapses, accompanied by motor abnormalities and reduced lifespan. Remarkably, these phenotypes were partially corrected by foxo inhibition, bolstering the potential pharmacological management of muscle intrinsic abnormalities associated with ALS. The findings demonstrate an intrinsic muscle dysfunction in ALS, which can be modulated by targeting FOXO factors, paving the way for novel therapeutic approaches that focus on the skeletal muscle as complementary target tissue.


  • Defining the landscape of TIA1 and SQSTM1 digenic myopathy

    by Paula Panos-Basterra, Julian Theuriet, Aleksandra Nadaj-Pakleza, Armelle Magot, Beatrice Lannes, Pascale Marcorelles, Anthony Behin, Marion Masingue, Florence Caillon, Yannis Malek, et al.


  • Open Access

    Dysregulated FOXO1 activity drives skeletal muscle intrinsic dysfunction in amyotrophic lateral sclerosis

    by Mónica Zufiría, Oihane Pikatza-Menoio, Maddi Garciandia-Arcelus, Xabier Bengoetxea, Andrés Jiménez, Amaia Elicegui, Maria Levchuk, Olatz Arnold-García, Pablo Iruzubieta, Jon Ondaro, et al.

    Amyotrophic Lateral Sclerosis (ALS) is a multisystemic neurodegenerative disorder, with accumulating evidence indicating metabolic disruptions in the skeletal muscle preceding disease symptoms, rather than them manifesting as a secondary consequence of motor neuron (MN) degeneration. Hence, energy homeostasis is deeply implicated in the complex physiopathology of ALS and skeletal muscle has emerged as a key therapeutic target. Here, we describe intrinsic abnormalities in ALS skeletal muscle, both in patient-derived muscle cells and in muscle cell lines with genetic knockdown of genes related to familial ALS, such as TARDBP (TDP-43) and FUS . We found a functional impairment of myogenesis that parallels defects of glucose oxidation in ALS muscle cells. We identified FOXO1 transcription factor as a key mediator of these metabolic and functional features in ALS muscle, via gene expression profiling and biochemical surveys in TDP-43 and FUS silenced muscle progenitors. Strikingly, inhibition of FOXO1 mitigated the impaired myogenesis in both the genetically modified and the primary ALS myoblasts. In addition, specific in vivo conditional knockdown of TDP-43 or FUS orthologs ( TBPH or caz ) in Drosophila muscle precursor cells resulted in decreased innervation and profound dysfunction of motor nerve terminals and neuromuscular synapses, accompanied by motor abnormalities and reduced lifespan. Remarkably, these phenotypes were partially corrected by foxo inhibition, bolstering the potential pharmacological management of muscle intrinsic abnormalities associated with ALS. The findings demonstrate an intrinsic muscle dysfunction in ALS, which can be modulated by targeting FOXO factors, paving the way for novel therapeutic approaches that focus on the skeletal muscle as complementary target tissue.

  • Phenotype variability and natural history of X-linked myopathy with excessive autophagy

    by Gorka Fernández-Eulate, Girolamo Alfieri, Marco Spinazzi, Isabelle Ackermann-Bonan, Fanny Duval, Guilhem Solé, Florence Caillon, Sandra Mercier, Yann Pereon, Armelle Magot, et al.

    Objective X-linked myopathy with excessive autophagy (XMEA) linked to the VMA21 gene leads to autophagy failure with progressive vacuolation and atrophy of skeletal muscles. Current knowledge of this rare disease is limited. Our objective was to define the clinical, radiological, and natural history of XMEA. Methods We conducted a retrospective study collecting clinical, genetic, muscle imaging, and biopsy data of XMEA patients followed in France and reviewed the literature for additional cases. Results Eighteen males had genetically confirmed XMEA in France, carrying four different VMA21 variants. Mean age at disease onset was 9.4 ± 9.9 (range 1–40) years. In 14/18 patients (77.8%), onset occurred during childhood (< 15 years); however in four patients, the disease started in adulthood. Patients had anterior and medial compartment thigh muscle weakness, distal contractures (56.3%), elevated CK levels (1287.9 ± 757.8 U/l) and autophagic vacuoles with sarcolemmal features on muscle histopathology. Muscle MRI (n = 10) showed a characteristic pattern of lower limb muscle involvement. In 11 patients, outcome measures were available for an average follow-up period of 10.6 ± 9.8 years and six of them show disease progression. Mean change of functional outcomes was 0.5 ± 1.2 points for Brooke and 2.2 ± 2.5 points for Vignos score, 7/16 patients (43.8%) needed a walking aid and 3/16 (18.8%) were wheelchair-bound (median age of 40 years old, range 39–48). The variant c.164-7 T > G was associated with a later onset of symptoms. Respiratory insufficiency was common (57.1%) but cardiac involvement rare (12.5%). Interpretation XMEA has variable age of onset, but a characteristic clinical, histopathological, and muscle imaging presentation, guiding the diagnosis. Although slowly, motor disability progresses with time, and relevant genotype–phenotype correlations will help design future clinical trials.